Edwards Lifesciences EW
NYSE EW
$90.09 -2.19 (-2.37%)
At close: Aug 20, 2026 · 1:22 PM UTC

Edwards Lifesciences (EW) Asset Writedowns and Impairment (2017 - 2026)

Edwards Lifesciences (EW) posted quarterly Asset Writedowns and Impairment of $123.6 million for Q1 2026, down 15.86% quarter-over-quarter from $146.9 million in Q4 2025.

Edwards Lifesciences (EW) Asset Writedowns and Impairment (2017 - 2026) Analysis & Trends

Edwards Lifesciences' Asset Writedowns and Impairment history runs 4 years deep, the most recent figure standing at $123.6 million for Q1 2026.

  • In Q1 2026, Asset Writedowns and Impairment changed N/A year-over-year to $123.6 million; the TTM figure through Mar 2026 stood at $357.6 million (changed N/A YoY), while the FY2025 annual figure was $186.9 million, changed N/A from the prior year.
  • Asset Writedowns and Impairment for Q1 2026 stood at $123.6 million, down from $146.9 million in the prior quarter.
  • The five-year high for Asset Writedowns and Impairment was $146.9 million in Q4 2025, with the low at $40.0 million in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Abbott Laboratories 198.95 Bn 193.35 Bn 7.27 Bn
2 Stryker 128.10 Bn 124.63 Bn 4.50 Bn
3 Medtronic 118.91 Bn 109.69 Bn 6.41 Bn
4 Boston Scientific 73.43 Bn 72.89 Bn 3.85 Bn
5 Edwards Lifesciences 51.91 Bn 47.66 Bn 1.35 Bn
6 Dexcom 34.52 Bn 32.58 Bn 830.00 Mn
7 GE HealthCare Technologies 33.94 Bn 31.83 Bn 2.18 Bn
8 Koninklijke Philips 26.37 Bn 23.05 Bn 4.55 Bn
9 Steris 23.14 Bn 22.66 Bn 684.20 Mn
10 Zimmer Biomet Holdings 19.29 Bn 18.88 Bn 1.54 Bn

Historic Data

Download Data
DateValue
Jun 30, 2026 40.00 Mn
Jun 30, 2026 40.00 Mn
Mar 31, 2026 123.60 Mn
Mar 31, 2026 123.60 Mn
Dec 31, 2025 146.90 Mn
Dec 31, 2025 146.90 Mn
Sep 30, 2025 40.00 Mn
Sep 30, 2025 40.00 Mn
Jun 30, 2025 47.10 Mn
Jun 30, 2025 47.10 Mn
Dec 31, 2019 -32.50 Mn
Dec 31, 2019 -32.50 Mn
Sep 30, 2019 26.90 Mn
Sep 30, 2019 26.90 Mn
Jun 30, 2019 46.20 Mn
Jun 30, 2019 46.20 Mn
Dec 31, 2017 -31.00 Mn
Dec 31, 2017 -31.00 Mn